ZEVASKYN commercial ramp is progressing with 3 patients treated in Q1 and 6+ biopsies expected in Q2, but the company remains pre-profitability with widening losses. The $168.3M cash runway provides ~2 years of funding at current burn rates. The ABO-701 licensing adds pipeline optionality but is early-stage (IND filing H2 2027). Monitor Q2 patient treatment cadence and any guidance on revenue trajectory.
Price Chart
Executive Summary
Abeona Therapeutics reported Q1 2026 net product revenue of $8.7M, up from $2.4M in Q4 2025, driven by three ZEVASKYN patient treatments. Net loss widened to -$17.1M (-$0.30/share) from -$12.0M (-$0.24/share) in Q1 2025, reflecting increased SG&A costs from commercial scaling and a $7.0M upfront licensing payment for the new ABO-701 T-cell therapy program. Cash and investments totaled $168.3M, down from $191.4M at year-end 2025.
Key Financial Metrics
Key Facts
- Q1 2026 net product revenue of $8.7M vs $2.4M in Q4 2025 (quarter-over-quarter increase of $6.3M)
- Three ZEVASKYN patient treatments completed in Q1 2026; one additional in early Q2
- QTC network expanded to six sites with activation of NY-Presbyterian/Columbia and CHOP
- Net loss of -$17.1M (-$0.30/share) vs -$12.0M (-$0.24/share) in Q1 2025
- Cash, cash equivalents and short-term investments of $168.3M as of March 31, 2026
- In-licensed ABO-701 (PSMA-SIR-T) engineered T-cell therapy for prostate cancer; $7.0M upfront payment
- Ophthalmology programs deprioritized as part of portfolio optimization
- Published coverage policies in place for 95% of commercially insured U.S. lives
Financial Impact
Q1 2026 net product revenue $8.7M; net loss -$17.1M; cash burn ~$23.1M in Q1
Risk Factors
- Commercial execution risk — ZEVASKYN revenue still nascent with only 3 patients treated in Q1
- Widening net loss and operating expenses as commercial infrastructure scales
- ABO-701 is pre-clinical; IND filing not expected until H2 2027 with no near-term value
- Cash burn of ~$23M/quarter; runway of ~7 quarters at current pace
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-022610 |
| Document: form8-k.htm | 0001493152-26-022610 |
| Document: 0001493152-26-022610-index-headers.html | 0001493152-26-022610 |
| Document: 0001493152-26-022610-index.html | 0001493152-26-022610 |
| Document: 0001493152-26-022610.txt | 0001493152-26-022610 |
| 8-K Data (Synthetic) | 0001493152-26-022610 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 8-K | $5.47 $5.57 | ▲ +1.83% | ▲ +1.01% | $5.03 (−8.14%) |
Aug 14, 2026 6w ago | Institutional Cluster | $5.94 $6.06 | ▲ +2.02% | ▲ +3.21% | $5.03 (−15.40%) |
Aug 13, 2026 7w ago | 8-K | $6.35 $5.96 | ▼ −6.07% | ▼ −4.10% | $5.03 (−20.80%) |
Aug 13, 2026 7w ago | Press Release | $6.35 $5.96 | ▼ −6.07% | ▼ −4.10% | $5.03 (−20.80%) |
Jul 9, 2026 12w ago | Insider Cluster | $6.98 $7.02 | ▲ +0.57% | ▲ +1.13% | $5.03 (−28.01%) |
Jun 15, 2026 15w ago | Insider Cluster | $5.65 $5.72 | ▲ +1.24% | ▲ +3.47% | $5.03 (−11.06%) |
Jun 15, 2026 15w ago | Insider Cluster | $5.65 $5.72 | ▼ −1.24% | ▼ −3.47% | $5.03 (+11.06%) |
Jun 12, 2026 16w ago | 8-K | $5.53 $5.77 | ▲ +4.34% | ▲ +3.67% | $5.03 (−9.13%) |
Jun 10, 2026 16w ago | 8-K | $5.53 $5.65 | ▲ +2.17% | ▲ +1.74% | $5.03 (−9.13%) |
Jun 10, 2026 16w ago | Insider Cluster | $5.36 $5.65 | ▼ −5.41% | ▼ −1.98% | $5.03 (+6.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access